Search Results - Andrianov, Vasily

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

    748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors by Sanborn, Rachel E, Furqan, Muhammad, Laux, Doug, Sharma, Manish, Olson, Daniel, Berz, David, Hauke, Ralph J, Massarelli, Erminia, Steuer, Conor, Davis, Elizabeth, Iams, Wade T, Thompson, Jonathan, Hamm, John, Andrianov, Vasily, O’Neill, Brianne, Durana, Yaiza Diaz De, Tolcher, Anthony W

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

    742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors by Park, Jong Chul, Berz, David, Sharma, Manish, Massarelli, Erminia, Hauke, Ralph J, Tsai, Frank Yung-Chin, Hong, David, Akhave, Neal, Call, Justin A, Carlisle, Jennifer, Sanborn, Rachel E, Haas, Naomi B, Hamm, John, Ross Camidge, D, Spira, Alexander I, Andrianov, Vasily, O’Neill, Brianne, Kinkead, Heather, Tolcher, Anthony W

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Under-Reporting of Patient-Reported Outcome in Hematological Malignancies Trials

    Under-Reporting of Patient-Reported Outcome in Hematological Malignancies Trials by Vidal, Liat, Messina, Anthony J, Vidal, Laura, Andrianov, Vasily, Curtis, Kelly K., Moss, Keren R.

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Under Reporting of Patient Reported Outcomes (PROs) in Myeloproliferative Neoplasm (MPN) Clinical Trials

    Under Reporting of Patient Reported Outcomes (PROs) in Myeloproliferative Neoplasm (MPN) Clinical Trials by Messina, Anthony J, O'Brien, Quentin E, Andrianov, Vasily, Moss, Keren R., Vidal, Laura, Vidal-Fisher, Liat

    Published in Blood
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

    Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma by Subbiah, Vivek, Chawla, Sant P, Conley, Anthony P, Wilky, Breelyn A, Tolcher, Anthony, Lakhani, Nehal J, Berz, David, Andrianov, Vasily, Crago, William, Holcomb, Monica, Hussain, Abrahim, Veldstra, Carson, Kalabus, James, O'Neill, Brianne, Senne, Lane, Rowell, Emily, Heidt, Analeah B, Willis, Katelyn M, Eckelman, Brendan P

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  6. 6
    Recombinant Alpha-1 Antitrypsin-Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study

    Recombinant Alpha-1 Antitrypsin-Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study by Brantly, Mark L, Kuhn, Brooks T, Farah, Humam W, Mahadeva, Ravi, Cole, Alexandra, Chang, Catherina L, Brown, Cynthia D, Campos, Michael A, Lascano, Jorge E, Babcock, Erin K, Bhagwat, Sharvari P, Boyea, Teresa F, Veldstra, Carson A, Andrianov, Vasily, Kalabus, James L, Eckelman, Brendan P, Veale, Andrew G

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Charmed particles production in pA-interactions at 70 GeV

    Charmed particles production in pA-interactions at 70 GeV by Ryadovikov, Vasily

    Get full text
    Items that this one cites
    Conference Proceeding
    Save to List
    Saved in:

Search Tools: